Update on the Diagnosis and Management of CTEPH in Latin America

Slides:

Advertisements

Similar presentations

Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and post- pulmonary endarterectomy pulmonary hypertension A pre-defined subgroup.

Advertisements

What You Need to Know About CTEPH Today: A Status Update Moderator David Langleben, MD, FRCPC Professor of Medicine McGill University Director Center for.

Latin American Symposium Future Perspectives in Pulmonary Hypertension.

The VERITY Steering Committee

A Framework for Diagnosing and Treating CTEPH

NOACs for Cancer-Associated Thrombosis:

A Paradigm Shift in PAH.

The Clinical Enigma of Cardiogenic Shock

Identifying and Managing Dyspnea Associated With CTEPH

UNDERSTANDING RISK STRATIFICATION IN PAH:

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Metastatic Renal Cell Carcinoma

Select Topics in Cardiovascular Medicine

Pulmonary Embolism Scope of the Problem Massive vs Submassive Pulmonary Embolism.

New Treatments for CTEPH

Follow-Up of the Patient After PE

Decision-making in the eRA of Treating to Target

PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence

Improving Risk Assessment and Early Diagnosis in PAH

Are We Closer to Personalized Medicine in MS?

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

Approaches to the Patient With a Runny Nose

WHO Clinical Classification of PH Complex Cases in PH.

Learning Objectives Current Practices in Ruling Out AMI.

Selected Highlights of the Latest Advances in PAH

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.

Battling Constipation

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Updated Guideline Recommendations for the Definitive Diagnosis of Unexplained Syncope.

Primary Biliary Cholangitis

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Current and Emerging Data in CTEPH

Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea

Oral Prostanoids and PAH

Program Goals Overview Is NEDA a Reasonable Target?

Identifying Strategies for Improving Outcomes in Patients With CTEPH

When Is Intrathecal Drug Delivery Appropriate?

Program Goals Disclaimers Defining Refractory Seizures.

New ELN Recommendations

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Familial Chronic Thromboembolic Pulmonary Hypertension

Critical Decision Points in Insomnia

NOAC Studies in VTE AF Studies Superior Outcomes.

Pulmonary Hypertension Updates From 2018

Communicating With Your Patients About Major Depressive Disorder

Incorporating Prostacyclins Into Practice

Program Goals Background: Anticoagulation in Patients With VTE.

Operability assessment in CTEPH: Lessons from the CHEST-1 study

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

CTEPH in Clinical Practice

Clinical Challenges and Updates in Managing Seizure Clusters

Assessing the Burden of Hyperkalemia

Program Goals Overview Is NEDA a Reasonable Target?

When Is Intrathecal Drug Delivery Appropriate?

Assessing the Burden of Hyperkalemia

Incorporating New PAH Treatments Into Clinical Practice

Clinical Comparisons in CTEPH

Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

Merging the Art and Science of Managing nOH in Clinical Practice

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Presentation transcript:

Update on the Diagnosis and Management of CTEPH in Latin America

Clinical Classification of PH

Pulmonary Endarterectomy Surgery: Scar Tissue Removal

Results of PE

History of PE Is a Risk Factor for CTEPH

Diagnosis of CTEPH (SCAR): A Step-Wise Process

SCAR: S = Suspect

SCAR: C = Confirm

SCAR: AR = Assess Risk

CTEPH Is Not Just a Clot Problem

CTEPH Is Not Just a Clot Problem (cont)

CTEPH Treatment Algorithm

Key Principles Regarding the Management of CTEPH

Key Principles Regarding the Management of CTEPH (cont)

CTEPH Treatment: Patients Deemed Operable

CTEPH Treatment Algorithm (cont)[a]

Pulmonary Endarterectomy Specimen: Significant Thromboembolic Material

UCSD Experience With Pulmonary Endarterectomy

UCSD Experience With Pulmonary Endarterectomy (cont)

CTEPH: Determining Operability

Potentially Inoperable Patient With CTEPH

CTEPH Treatment Algorithm (cont)

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CHEST-1)

Riociguat: Mechanism of Action

CHEST-1*: Mean Change From Baseline in 6MWD

CHEST-2: Long-Term Extension Study of Riociguat for CTEPH

AEs in the CHEST-2 Study

Potential Scenarios for Targeted Medical Therapy in CTEPH

Patient Offered BPA

Pulmonary Endarterectomy and BPA: Comments

Summary and Conclusions

Abbreviations

Abbreviations (cont)